Parkinson’s UK partners with UCL on phase II trial – PharmaTimes

Parkinson’s UK has partnered with University College London (UCL) and will invest £1m in a phase II clinical trial to investigate if the drug ondansetron can alleviate hallucinations in people with Parkinson’s disease.

The trial will explore if ondansetron, a drug currently used to treat nausea in chemotherapy patients, is safe and effective against hallucinations in people with Parkinson’s.

Currently, there are 145,000 people living with Parkinson’s in the UK and 75% will experience visual hallucinations at some pint.

Click here to read full article http://www.pharmatimes.com/news/parkinsons_uk_partners_with_ucl_on_phase_ii_trial_1354754

Leave a Reply

Your email address will not be published. Required fields are marked *

Font Resize